Alphageneron Pharmaceuticals is focused on developing innovative NK cell-based cancer therapies that leverage the body's immune system to combat cancer. Their lead product, ENKASTIM™, is an autologous therapy that utilizes the patient's own natural killer (NK) cells, activating them to specifically target cancer cells that express membrane Hsp70 (mHsp70), a biomarker associated with aggressive tumors. This targeted approach aims to minimize damage to healthy cells while effectively attacking cancerous ones. Additionally, the company is advancing AP-161™, an allogeneic NK cell therapy that also targets mHsp70-expressing tumors, and AP-205™, which is designed as an 'off-the-shelf' allogeneic CAR-engineered NK cell therapy for the same purpose.

Furthermore, Alphageneron is developing AP-401™, a novel therapy that employs Induced Pluripotent Stem Cell (iPSC) technology to create bi-specific CAR NK cells targeting CD155 and CD73. This innovative approach has demonstrated promising efficacy against solid tumors in preclinical studies, highlighting the potential of combining CAR technology with NK cell therapy to enhance anti-tumor responses. Overall, Alphageneron Pharmaceuticals is at the forefront of harnessing NK cell technology to create targeted therapies that could significantly improve outcomes for cancer patients.

United States

Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing Antibody Drug Conjugates (ADCs) and natural killer (NK) cell therapies, supported by Companion Diagnostics. Our team are industry veterans with experience in both large pharma and biotechnology startups committed to transforming the lives of cancer patients.

Alphageneron Pharmaceuticals

Company Details